Showing results (2131-2140 of 6,065) with videos related to

Sort By:
Pageof 607
Hypertension (Dallas, Tex. : 1979)|December 1, 1994
Beta-adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic ratsM Böhm, M Moll, B Schmid, et al.
Research and Practice in Thrombosis and Haemostasis|July 7, 2023
Advanced practice provider-led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilizationCassiopeia Frank, Raj Kasthuri, Nigel S Key, et al.
The American Journal of Cardiology|July 11, 2002
Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaquesJon D Laman, Arjan H Schoneveld, Frans L Moll, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 2, 2003
[A diagnostic decision rule for managing children with signs of meningeal irritation]R Oostenbrink, K G Moons, G Derksen-Lubsen, et al.
Therapeutic Drug Monitoring|November 13, 2020
Exploring Reference Values for Hair Cortisol: Hair Weight Versus Hair ProteinNadine Frisch, Anna Eichler, Anne-Christine Plank, et al.
The American Journal of Pathology|May 1, 1987
Immunocytochemical analysis of Ewing's tumors. Patterns of expression of intermediate filaments and desmosomal proteins indicate cell type heterogeneity and pluripotential differentiationR Moll, I Lee, V E Gould, et al.
Journal of the International AIDS Society|November 26, 2021
Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South AfricaMegan A Grammatico, Anthony P Moll, Koeun Choi, et al.
Frontiers in Immunology|June 24, 2020
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and EfficacyGuido Moll, Norman Drzeniek, Julian Kamhieh-Milz, et al.
Audiology & Neuro-Otology|April 6, 2005
In vitro isolation and cell culture of vestibular inner ear melanocytesMarcos Sanchez Hanke, Sabine Kief, Rudolf Leuwer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devicesStephan Moll, Peter Kenyon, Luigi Bertoli, et al.
Pageof 607